78 results about "Gut barrier" patented technology

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

The invention discloses a curcumin nanocrystal preparation as well as a preparation method and application thereof. The invention relates to a curcumin nanocrystal composition which is prepared by drying and curing a curcumin nanocrystal suspension to a blank pellet core, the curcumin nanocrystal suspension contains 20-35% of curcumin nanocrystals, 1-10% of a three-dimensional protective agent and 1-10% of a charge protective agent, and the average particle size of the curcumin nanocrystals is 200-320 nm. The curcumin nanocrystal composition prepared by the invention can effectively prevent and treat heat stroke and complications thereof, remarkably improve heat tolerance, prolong survival time, reduce the level of inflammatory factors in blood, protect intestinal epithelial cells and intestinal barrier functions, reduce damage caused by heat stroke, prevent and treat body and organ damage caused by heat stroke, and improve the curative effect of the curcumin nanocrystal composition. The preparation has the advantages of being high in drug loading capacity, good in stability, high in bioavailability, safe, effective, convenient to carry and the like.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

This invention belongs to the field of anti-aging functional food technology, specifically relating to an anti-aging and longevity composition containing inactivated Akkermansia myxophilus. Existing anti-aging products are mostly single-ingredient products. The composition of this invention contains inactivated Akkermansia myxophilus, NMN, coenzyme Q10, resveratrol, and astaxanthin. This invention achieves the effects of delaying aging, improving muscle strength, and enhancing cognitive function by repairing the intestinal barrier, increasing NAD+ levels, and activating longevity pathways. The composition of this invention is stable at room temperature and can be formulated into capsules or powder.

The application relates to the technical field of organ chip, and discloses a biocompatible membrane sheet, which comprises wave structures continuously distributed in one direction, and the wave structures are in a hollow structure. The biocompatible membrane sheet disclosed by the application has consistent hollow wrinkle forms, uniform deformation when the biocompatible membrane sheet is subjected to external force, better transmission and fluctuation, and can more truly reproduce the dynamic change state of an organ in vitro. The application further discloses an organ chip, an intestinal organ chip, an intestinal organ chip system, a membrane sheet preparation method, an intestinal organ chip preparation method and an intestinal barrier construction method.

This invention discloses Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. It belongs to the field of microbial shell-core gel technology, and particularly relates to Bifidobacterium microspheres for alleviating Salmonella typhimurium infection. The Bifidobacterium microspheres are prepared by mixing a thermal copolymer with Bifidobacterium, then adding it dropwise to a calcium chloride aqueous solution for the first cross-linking, followed by immersion in a tannic acid aqueous solution for the second cross-linking. The thermal copolymer is obtained by mixing equal volumes of polysaccharide aqueous solution and protein aqueous solution. This invention provides Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. The Bifidobacterium microspheres prepared by this invention achieve concentrated responsive release of Bifidobacterium in the cecum, improving intestinal retention and adhesion colonization efficiency. Their alleviating effect on Salmonella typhimurium infection exceeds that of free bacteria, exhibiting better intestinal barrier damage repair and flora regulation effects.

The invention belongs to the technical field of medicine and pharmacy, and particularly relates to application of an AP1B1 allosteric activator of ethyl gallate. In the invention, AP1B1 is a beta 1 subunit (AP1B1) of a linking factor associated protein complex 1 (AP-1), and is an essential component for assembling a functional AP-1B complex. The ethyl gallate is used as an allosteric activator of AP1B1 and is specifically combined with an allosteric pocket of the AP1B1 to induce the AP1B1 to generate conformational change, so that the vesicle transportation function of an AP1B complex is activated, and the substrate-side membrane protein sorting capacity is recovered. A target dependence experiment verifies that the effect of ethyl gallate on promoting tight junction protein ZO-1 expression and membrane localization in AP1B1 knocked-down Caco-2 cells is remarkably weakened, and it is prompted that the intestinal barrier protection function of ethyl gallate depends on AP1B1. The invention provides a new strategy for developing medicines for treating intestinal barrier injury related diseases.

The invention relates to application of golden chrysanthemum leaf extract in preparation of intestinal mucosal lesion products, and belongs to the technical field of medicine and health care products. The extract mainly comprises phenolic acid components, has no obvious visceral toxicity, and realizes protection of intestinal mucosal injury caused by hypoxia or chemical drugs by regulating intestinal barrier function, oxidative stress, inflammatory response and energy metabolism. The invention breaks through the limitation of the existing single-target drug, provides a multi-channel protection scheme, is suitable for developing anti-hypoxia functional products (such as drugs, health care products or foods), and improves the economic value of golden chrysanthemum leaf resources.

The invention belongs to the field of biological medicine, and particularly discloses an acute intestinal injury targeted therapy drug based on an MAIT cell viability evaluation algorithm and application thereof. The MAIT cell activity parameters (including CD3 + TCR beta + MR1 + cell proportion and IL-17A secretion volume) in a patient sample are detected through flow cytometry, quantification is carried out according to an algorithm activity score = (MR1 + cell proportion * 0.4) + (IL-17A concentration / 50 * 0.6), and the patient with the score larger than or equal to 2.0 is suitable for targeted therapy. An oral solution (with the concentration of 5-20 [mu] M) taking acetyl-6-formyl pterin (Ac-6FP) as a core is adopted for treatment, intestinal injury is relieved by specifically inhibiting the IL-17A secretion function of MAIT cells, the intestinal barrier function is remarkably improved in an animal model, and the survival rate is increased. Meanwhile, the matched kit integrates the antibody detection assembly and the Ac-6FP medicine, and diagnosis and treatment integration is achieved. The invention provides a precise targeted treatment strategy and medicine for acute intestinal injury.

This invention provides a composition for alleviating intestinal oxidative stress damage and its application, the composition comprising 4'-galactosyllactose (4'-GL) and glycomacropeptide (GMP). This invention found that, compared with the individual concentrations of 4'-GL and GMP, the composition of 4'-GL and GMP more significantly promotes the release of superoxide dismutase and catalase, while also more significantly reducing the release of malondialdehyde, a marker of oxidative stress. The synergistic effect between the two allows 4'-GL and GMP to better alleviate intestinal damage in Drosophila. Simultaneously, the composition can improve the survival rate and climbing index of H2O2-induced Drosophila, prolong the intestinal length of diseased Drosophila, improve the integrity of the intestinal barrier, and induce a recovery trend in the Drosophila. This demonstrates that the composition has a mitigating effect on intestinal oxidative stress damage.

The invention relates to an establishment method of a high-fat induced intestinal organ injury model and an injury intervention method for the model. The establishment method comprises the following steps: step A, preparation: preparing colon cells, PBMC cells and an organ-like culture chip for later use; step B, colon barrier construction: inoculating colon cells to the surface of a barrier membrane on the lower side of a culture chip by using an organoid culture chip to obtain a colon barrier model; step C, constructing a co-culture model, and inoculating PBMC cells to the basal side of the colon barrier on the basis of the colon barrier to obtain a human colon barrier-PBMC co-culture model; d, constructing a damage model, and performing damage treatment on the co-culture model by using a treating fluid to obtain the damage model; according to the invention, the barrier function organ-like chip is used, a human intestinal cell-PBMC co-culture model is formed by utilizing human intestinal organs and PBMC cells, and OXLDL / palmitic acid can play a role in an injured intestinal organ barrier model and form a high-fat induced intestinal organ injury model through the prepared injury treating fluid.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

The application provides a soluble acid polysaccharide of Phaseolus vulgaris, and also provides a preparation method and application of the soluble acid polysaccharide of Phaseolus vulgaris. The application also provides application of the soluble acid polysaccharide of Phaseolus vulgaris in preparation of a medicine for protecting the spleen and liver, having the ability of recovering the colon barrier, regulating intestinal flora, or a health-care food for enhancing the immunity of the body. The soluble acid polysaccharide of Phaseolus vulgaris can be extracted by hot water extraction or microwave-assisted low eutectic solvent extraction, especially, the polysaccharide extracted by the microwave-assisted low eutectic solvent extraction has better drug efficacy, is safer and more controllable, and provides a new selection for clinic.

Methods and systems for assessing gut barrier function with medical imaging techniques and orally ingested contrast are discussed herein. For example, a method for assessing gut health of a patient includes administering a contrast agent to the patient. The method further includes performing an magnetic resonance imaging (MRI) scan of the patient. The method further includes determining a metric corresponding to the contrast agent in a gut of the patient based on the performed MRI scan. The method further includes assessing health of the gut of the patient based on the metric corresponding to the contrast agent in the gut of the patient.

The present invention relates to the use of riboprine in the maintenance, improvement, or dietary management of gut barrier function. The riboprine may be formulated in an oral composition such as dietary supplement, a food product, a food for special medical purpose (FSMP) or a food for special dietary use (FSDU).

The present invention is directed to a dietary supplement composition for enhancing gut barrier and skin health comprising a therapeutically effective amount of: (a) at least one polysaccharide chosen from a fructo-oligosaccharide, a galacto-oligosaccharide, a xylo-oligosaccharide, and mixtures thereof; (b) at least one polysaccharide mucilage having demulcent activity; (c) at least one source of insoluble dietary fiber having antioxidant activity; (d) at least one amino acid capable of supporting gut barrier integrity; (e) at least one source of resistant starch; and, optionally (f) at least one natural ingredient capable of protecting gastric function.

This invention belongs to the field of food nutrition and functional factors, specifically relating to a method for preparing highly immunomodulatory ovotransferrin (OVT) hydrolysates based on an adult gastrointestinal simulated digestive system. The method involves processing OVT using a simulated adult gastrointestinal tract to prepare OVT hydrolysates containing HTEGSTT, TTSY, and / or RTAGWVIPMG. This invention reveals that OVT exhibits enhanced immunomodulatory activity after gastrointestinal digestion and hydrolysis, and is more readily hydrolyzed in simulated adult digestive fluids than in infant digestive fluids. Comparative experiments show that nutritional intervention with OVT simulated digestive products from adults and infants can promote the production of short-chain fatty acids such as acetic acid, propionic acid, and butyric acid, effectively alleviate swelling and damage to the small intestinal mucosa caused by inflammation, significantly improve intestinal barrier immune function, and OVT IA exhibits higher intestinal immune activity than OVT IB.

Bacillus strain compositions and methods for converting (i) one or more polysaccharides into short chain polysaccharides and / or monosaccharides and / or (ii) one or more proteins into short chain polypeptides and / or amino acids are provided. The Bacillus strain composition can comprise Bacillus subtilis 750 or an active variant thereof, and optionally at least one of Bacillus subtilis 747, Bacillus subtilis 839, Bacillus subtilis 1781, Bacillus subtilis 1999, Bacillus subtilis 2018, or an active variant thereof. Compositions provided herein can be fed to animals in an effective amount to increase digestibility of one or more polysaccharides and / or one or more proteins; increase nutrition efficiency and / or energy partitioning; increase nutrient absorption; enhance gut immunity and / or gut barrier integrity; and / or inhibit a pathogen in the gastrointestinal tract of the animal.

The present invention relates to a composition comprising xylooligosaccharides (XOS), inulin and magnesium (Mg). The composition is particularly suited for use in improving the gastrointestinal microbiota, and maintaining and / or improving gut barrier integrity, and increasing the bioavailability of Mg in an individual. A method of preparing said composition and the use of said composition as a dietary supplement or a medicament are also disclosed.

The invention provides a liver cancer early warning and risk assessment method based on intestinal microbiome, and relates to the technical field of medical auxiliary analysis, by collecting excrement and plasma samples of high-risk groups and combining 13C-cholic acid dynamics, functional gene abundance and intestinal barrier indexes, a multi-modal risk score is calculated, and dynamic monitoring is realized through longitudinal CUSUM. When the risk index exceeds a threshold value, the system can give out an early warning to assist iconography review and personalized intervention. According to the method, high-risk individuals of liver cancer can be identified in serum AFP and iconography unabnormal stages, early intervention and follow-up visit optimization are achieved, prediction sensitivity is high, interpretability is high, and the method is suitable for high-risk groups of HBV / liver cirrhosis and metabolic liver diseases and has remarkable clinical application value and generalizability.

The invention relates to the technical field of microorganisms and biological medicines, in particular to triple probiotics as well as a preparation method and application thereof, and the triple probiotics comprise at least one probiotic of bacillus, lactobacillus acidophilus and bifidobacterium longum. The triple probiotics provided by the invention form an'oxygen consumption-enzyme production-acid production 'synergistic chain, and through synergistic degradation of uric acid, inhibition of excessive growth of conditioned pathogens and enhancement of intestinal barrier functions, the blood uric acid level of patients with asymptomatic hyperuricemia is reduced, the alpha-diversity of intestinal tracts is improved, the abundance of butyric acid producing bacteria is improved, and the content of the butyric acid producing bacteria is improved. The ratio of escherichia coli to shigella is reduced; sIBO is effectively relieved or reversed, and digestive tract symptoms such as abdominal distension and exhaust are reduced. In addition, the triple probiotics avoid liver and kidney toxicity caused by chemical drugs, and are suitable for long-term administration.

The invention discloses polygalacturonic acid (PGA) and application of a neohesperidin dihydrochalcone (NHDC) or neohesperidin (NH) embedded compound of the polygalacturonic acid (PGA) in preparation of anti-allergic food or drugs. The PGA has good biocompatibility and immune regulation and intestinal barrier repair functions. Experiments show that the PGA can significantly reduce IgE-mediated food anaphylaxis, alleviate allergic symptoms and improve intestinal structures. PGA is adopted as a carrier, and the PGA and NHDC / NH form non-covalent binding through intermolecular force to prepare the PGA-NHDC / PGA-NH compound, so that the solubility and the stability of the NHDC / NH are improved, and a synergistic anti-allergic effect is also generated. The PGA-NHDC / PGA-NH compound has the advantages of small molecular weight, fast absorption and non-immunogenicity, and can release NHDC / NH in colon in a targeted manner. On the basis, the invention further provides the application of the PGA-NHDC / PGA-NH compound in preparation of the orange juice, the obtained juice system is in a stable suspension state, has no precipitation layering phenomenon, has targeted synergistic antianaphylaxis and high storage stability, and remarkably improves the functionality and the storage stability of the juice.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

The invention discloses a composition for reducing liver injury. The composition for reducing liver injury comprises fucoidin and ginsenoside Rg1 in a mass ratio of (1-3): (1-3). Comprising fucoidin and ginsenoside Rg1 can be applied to preparation of drugs for relieving liver injury, drugs for promoting tissue blood supply and drugs for relieving NETs accumulation in the liver. It is found for the first time that chemotherapeutic drugs cause intestinal barrier damage, then LPS enters blood, and NETs-mediated inflammatory response is induced to aggravate in the liver. Based on pathogenesis study of the liver injury, on one hand, fucoidin and ginsenoside Rg1 are combined to reduce generation of NETs, inhibit accumulation of NETs in the liver and inhibit TF and MMP9 at the same time, and finally the liver injury is relieved; on the other hand, the fucoidin is combined with ginsenoside Rg1, so that intestinal barriers can be protected, LPS entering blood is reduced, tissue blood supply is promoted, and chemotherapy-induced liver injury is relieved.

The invention relates to bornyl acetate colon-targeted microspheres and a preparation method and application thereof.The bornyl acetate colon-targeted microspheres comprise bornyl acetate, sodium alginate, silk fibroin and zinc ions, are good in stability and slow-release performance, have better anti-inflammatory capacity, oxidative stress resistance, intestinal barrier repairing capacity and immunoregulation capacity, effectively treat ulcerative colitis and have good application prospects. And the effect is superior to that of a clinical medicine 5-aminosalicylic acid in multiple aspects.

The invention belongs to the field of biological medicine, and particularly relates to preparation and application of dextran for relieving ulcerative colitis. The dextran GS128 is formed by directly catalyzing and synthesizing dextransucrase Gtf128 generated by heterologous expression in vitro by taking sucrose as a substrate, and the product is obtained by ethanol precipitation, centrifugation, dissolution and dialysis. The compound shows high anti-digestion performance in the process of simulating gastrointestinal tract digestion, and can relieve the symptoms of ulcerative colitis by inhibiting oxidative stress, adjusting the balance of proinflammatory / anti-inflammatory factors and improving the colon barrier.